During the trial, participants will visit the study site several times over a few months. At each visit they will answer a questionnaire called the Timeline Follow-back, which asks them to recall how much alcohol they drank each day, and they will have a blood test for Carbohydrate Deficient Transferrin, a marker that can show heavy alcohol use. The study will also monitor any side effects to see if the medication is safe and well‑tolerated. All information is collected in a confidential manner and participants can stop at any time.

Table of Contents

• Trial overview
• Who can take part
• Study design and treatment
• What the study measures
• Trial phase and status
• Why this research matters

Trial overview

The available trial data describe one interventional study of ROPINIROLE in healthy volunteers.^[1] The study is designed to test whether a single oral dose changes metacognition and resting-state functional brain connectivity.^[1]

The trial title and summary show that the main focus is not a disease treatment study, but a mechanistic study of how ROPINIROLE may affect self-monitoring and brain network activity in people without a known illness.^[1]

Who can take part

The target population is healthy adults, described in the trial as healthy volunteers.^[1] The study does not list a disease group, so it is aimed at understanding the drug’s effect in people without the condition being studied.^[1]

The enrollment goal is 20 participants, which means this is a small study.^[1] Small studies like this are often used to explore a question before larger studies are done.^[1]

Study design and treatment

This is an interventional trial, meaning the researchers give a study treatment and then measure the effect.^[1] The intervention includes placebo and ROPINIROLE 1 mg given by mouth as a single dose.^[1]

Placebo is a look-alike treatment with no active study drug, and it is used to compare results fairly.^[1] The trial compares ROPINIROLE with placebo to see whether the drug changes confidence, accuracy, and brain connectivity.^[1]

What the study measures

The primary endpoint is the within-participant change in metacognitive efficiency, also called the M-ratio, under ROPINIROLE versus placebo.^[1] This is measured from confidence ratings during cognitive testing and uses a signal-detection-theoretic framework, which helps separate self-judgment from task performance.^[1]

The study uses a modified version of the Rey Auditory-Verbal Learning Test, which is a memory task that asks people to learn and recall words.^[1] Researchers use trial-by-trial accuracy and confidence ratings to see whether confidence matches actual performance.^[1]

The summary also says the study will look at metacognitive bias, meaning the gap between confidence and actual performance, and Goodman–Kruskal Gamma correlation, which shows how well confidence separates correct answers from errors.^[1] The brief summary states that the researchers want to know whether ROPINIROLE changes confidence without changing basic cognitive performance.^[1]

Trial phase and status

The trial is listed as Phase 4 and has the status Authorised.^[1] In the trial record, Phase 4 is linked with a product that already has marketing authorization and has been shown to be safe in humans.^[1]

Even though the product is already authorised, this study is still important because it asks a new research question about brain function and self-evaluation in healthy people.^[1]

Why this research matters

The trial summary explains that the researchers want to understand how dopaminergic stimulation may affect insight into one’s own performance.^[1] In simple terms, they are studying whether ROPINIROLE can make people more or less overconfident about their answers.^[1]

The study is also meant to help explain brain systems involved in self-awareness and unawareness of neurological disturbances, which is sometimes called anosognosia.^[1] The data suggest that findings from healthy volunteers may help guide future research on people who have problems with insight into their condition.^[1]

Table of contents

• Clinical trials overview
• Alcohol use disorder studies
• Asthma study
• Main endpoints and what they mean
• Who may take part
• Trial design and study status

Clinical trials overview

Current studies of LY3537031 are testing it in two different conditions: alcohol use disorder and uncontrolled moderate to severe asthma.^[1][2][3] These are interventional studies, which means researchers give a study treatment and compare results with placebo.^[1][2][3]

All three trials are listed as Authorised.^[1][2][3] Two studies are in Phase 3, and one study is in Phase 2.^[1][2][3]

Alcohol use disorder studies

Two Phase 3 trials are studying LY3537031 in people with alcohol use disorder, including one study in participants with moderate-to-severe alcohol use disorder.^[1][2] The planned enrollment is 949 participants in one study and 1,090 participants in the other.^[1][2]

The main goal in both alcohol studies is to show that at least one dose level is better than placebo for at least one of the dual primary endpoints.^[1][2] In simple terms, this means the researchers want to see whether LY3537031 helps people do better than placebo on the main results the study is designed to measure.^[1][2]

These studies also include a second period for responders, meaning people who improved in Period 1.^[1][2] In Period 2, the trial checks whether LY3537031 can help maintain a general reduction in alcohol consumption over time.^[1][2]

One alcohol study lists the primary outcome as behaviors associated with alcohol use disorder, measured by the Timeline Followback Method (TLFB).^[2] TLFB is a structured way to track drinking behavior over a set period.^[2]

Asthma study

One Phase 2 trial is studying LY3537031 in adult participants with uncontrolled moderate to severe asthma.^[3] The study plans to enroll 538 participants.^[3]

The main purpose of this trial is to compare LY3537031 with placebo and see whether it reduces severe asthma exacerbations.^[3] An asthma exacerbation is a worsening of asthma symptoms, often called a flare-up or attack.^[3]

The primary outcome is the annualized asthma exacerbation rate over 52 weeks of treatment, measured from baseline to Week 52.^[3] This means the study counts how often severe asthma flare-ups happen during the treatment period.^[3]

Main endpoints and what they mean

A primary endpoint is the main result a clinical trial uses to decide whether the treatment is working.^[1][2][3] In the alcohol studies, the endpoints focus on alcohol-related behavior and reduced alcohol consumption.^[1][2]

In the asthma study, the main endpoint is the rate of severe flare-ups during one year of treatment.^[3] This helps researchers understand whether the study treatment can lower the number of asthma worsening events over time.^[3]

Who may take part

The alcohol use disorder trials are for participants with alcohol use disorder, and one of them specifically names moderate-to-severe alcohol use disorder.^[1][2] The asthma trial is for adult participants with uncontrolled moderate to severe asthma.^[3]

Each study has its own entry rules, but the trial records show the main target groups clearly.^[1][2][3] The studies are designed for people who have the condition being tested, not for the general population.^[1][2][3]

Trial design and study status

All three studies are interventional and compare LY3537031 with placebo.^[1][2][3] The alcohol studies use a multi-period design, with an early period to test response and a later period to see whether benefits last in responders.^[1][2]

The asthma study follows participants for 52 weeks, which gives researchers a longer view of asthma control during treatment.^[3] All studies are currently marked as authorised, which means they have been approved to move forward in the trial process.^[1][2][3]

Table of Contents

• What is Valbenazine?
• How Does It Work?
• What Conditions Does Valbenazine Treat?
• How is Valbenazine Administered?
• Current Clinical Trials
• Potential Side Effects and Precautions

What is Valbenazine?

Valbenazine Ditosylate, also known as Valbenazine Tosylate or simply Valbenazine, is a medication being studied for its potential to treat certain movement disorders^[1]. It is developed by Neurocrine Biosciences Inc. and is currently undergoing clinical trials to evaluate its effectiveness and safety^[2].

How Does It Work?

Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein in the brain that helps package and transport certain chemicals (neurotransmitters) between brain cells. By inhibiting VMAT2, Valbenazine can help regulate the levels of these neurotransmitters, which may help control involuntary movements associated with certain disorders^[1].

What Conditions Does Valbenazine Treat?

Based on the ongoing clinical trials, Valbenazine is being studied for its potential to treat:

• Schizophrenia: Specifically, it’s being tested as an adjunctive (add-on) treatment for people with schizophrenia who have inadequate response to antipsychotic treatment^[1].
• Dyskinesia due to Cerebral Palsy (DCP): This includes choreiform movements, which are irregular, unpredictable, dance-like movements^[2].

It’s important to note that while these conditions are the focus of current studies, Valbenazine is not yet approved for treating these disorders. The clinical trials aim to determine its effectiveness and safety for these uses.

How is Valbenazine Administered?

Valbenazine is being tested in the form of oral capsules. In the clinical trials, it’s being administered once daily. The dosage varies depending on the study and condition being treated, ranging from 30 mg to 80 mg per day^[1][2].

Current Clinical Trials

There are currently two Phase 3 clinical trials studying Valbenazine:

1. Study for Schizophrenia: This trial is evaluating Valbenazine as an adjunctive treatment for people with schizophrenia who don’t respond adequately to antipsychotic treatment. The main goal is to see if Valbenazine can improve schizophrenia symptoms compared to a placebo^[1].

2. Study for Dyskinesia due to Cerebral Palsy: This trial is testing Valbenazine in both children and adults with dyskinesia (abnormal movements) caused by cerebral palsy. The primary aim is to see if Valbenazine can improve chorea (a type of involuntary movement) in these patients^[2].

Both studies are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either Valbenazine or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.

Potential Side Effects and Precautions

As Valbenazine is still in clinical trials, its full side effect profile is not yet known. However, based on the exclusion criteria in the studies, some precautions are being taken for people with:

• History of long QT syndrome or cardiac arrhythmia
• Moderate or severe liver problems
• History of neuroleptic malignant syndrome
• Substance use disorders
• Suicidal thoughts or behaviors

It’s important to remember that these are precautionary measures for the clinical trials and don’t necessarily reflect confirmed side effects or contraindications^[1][2].

As with any medication, if Valbenazine becomes approved for use, it will be crucial to discuss potential risks and benefits with a healthcare provider before starting treatment.

Table of Contents

• Introduction
• What is OSU6162?
• OSU6162 as a Treatment for Depression
• OSU6162 for Bipolar Depression
• How OSU6162 Works
• Dosage and Administration
• Potential Side Effects and Precautions
• Ongoing Research and Future Prospects

Introduction

OSU6162, also known as 3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride, is a promising medication currently being studied for its potential in treating depression and bipolar disorder. This article will provide an overview of OSU6162, its potential uses, and the ongoing research to evaluate its effectiveness and safety.^[1][2]

What is OSU6162?

OSU6162 is a drug that is being investigated for its potential to treat mental health conditions. It is also known by other names, including PNU-96391 hydrochloride and OSU-6162 hydrochloride. The medication comes in the form of a coated tablet and is taken orally.^[1][2]

OSU6162 as a Treatment for Depression

One of the main areas of research for OSU6162 is its potential use in treating depression, particularly in cases where other treatments have not been effective. Researchers are studying whether adding OSU6162 to existing treatments with selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) can help patients who haven’t responded well to these medications alone.^[1]

This research is particularly important because many people with depression don’t get better with standard treatments. The study aims to see if OSU6162 can help improve symptoms in these cases.

OSU6162 for Bipolar Depression

Another area of research for OSU6162 is its potential use in treating bipolar depression. Bipolar depression is the depressive phase of bipolar disorder, a condition characterized by alternating periods of depression and mania or hypomania.^[2]

Researchers are conducting an open-label study to assess how well OSU6162 works for people with bipolar depression and how well patients tolerate the medication. This research is important because finding effective treatments for bipolar depression can be challenging, and new options are needed.

How OSU6162 Works

OSU6162 is described as a dopaminergic stabilizer. This means it affects the way the brain uses dopamine, a neurotransmitter involved in mood regulation. While the exact mechanism is still being studied, it’s believed that OSU6162 may help balance dopamine activity in the brain, which could potentially improve mood symptoms in depression and bipolar disorder.^[2]

Dosage and Administration

In the ongoing studies, OSU6162 is being tested in the form of 15 mg coated tablets taken orally. The maximum daily dose being studied is 135 mg. However, it’s important to note that these dosages are part of research trials and may not reflect final recommendations if the drug is approved for general use.^[1][2]

Potential Side Effects and Precautions

As OSU6162 is still in the research phase, a complete profile of its side effects is not yet available. However, the studies have some exclusion criteria that give us an idea of potential concerns:

• People with certain heart conditions, particularly those affecting heart rhythm, may need to avoid the medication.
• The drug may interact with other medications, particularly those that affect liver enzymes or dopamine in the brain.
• People with a history of substance abuse, certain mental health conditions, or specific medical conditions may not be suitable candidates for the medication.^[1][2]

Ongoing Research and Future Prospects

OSU6162 is currently being studied in clinical trials to determine its effectiveness and safety. These trials involve carefully selected participants and controlled conditions. The results of these studies will help determine whether OSU6162 could become an approved treatment option in the future.^[1][2]

It’s important to note that while the initial research is promising, OSU6162 is not yet approved for general use. Patients should not attempt to use this medication outside of approved clinical trials. Always consult with a healthcare provider about treatment options for depression or bipolar disorder.